- Home
- CLPR vs NOTV Comparison
CLPR vs NOTV Comparison
Compare CLPR & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | NOTV |
|---|---|---|
| Founded | 2015 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 29.9M |
| IPO Year | 2017 | 1997 |
Fundamental Metrics
Financial Performance| Metric | CLPR | NOTV |
|---|---|---|
| Price | $3.53 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 58.1K | ★ 1.6M |
| Earning Date | 11-13-2025 | 12-03-2025 |
| Dividend Yield | ★ 10.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $154,179,000.00 | ★ $505,299,000.00 |
| Revenue This Year | N/A | $6.11 |
| Revenue Next Year | N/A | $4.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.90 | 0.85 |
| 52 Week Low | $3.39 | $0.66 |
| 52 Week High | $6.49 | $6.48 |
Technical Indicators
Market Signals| Indicator | CLPR | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 35.68 | 40.42 |
| Support Level | $3.57 | $0.84 |
| Resistance Level | $3.65 | $0.95 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 3.87 | 53.41 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.